Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Common Equity (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed Common Equity for 13 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 806.25% year-over-year to $11.1 million, compared with a TTM value of $11.1 million through Dec 2025, up 806.25%, and an annual FY2025 reading of $11.1 million, up 806.25% over the prior year.
  • Common Equity was $11.1 million for Q4 2025 at Abvc Biopharma, down from $14.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $14.5 million in Q3 2025 and bottomed at $515989.0 in Q2 2021.
  • Average Common Equity over 5 years is $5.6 million, with a median of $6.2 million recorded in 2022.
  • The sharpest move saw Common Equity skyrocketed 1679.2% in 2022, then tumbled 85.25% in 2024.
  • Year by year, Common Equity stood at $8.9 million in 2021, then crashed by 63.52% to $3.2 million in 2022, then surged by 107.29% to $6.7 million in 2023, then plummeted by 81.72% to $1.2 million in 2024, then skyrocketed by 806.25% to $11.1 million in 2025.
  • Business Quant data shows Common Equity for ABVC at $11.1 million in Q4 2025, $14.5 million in Q3 2025, and $9.5 million in Q2 2025.